한빛사논문
- 조회742
Chi-Pin James Wang a,b,1, Min Ji Byun a,b,1, Se-Na Kim c, Wooram Park d, Hee Ho Park e, Tae-Hyung Kim f, Jung Seung Lee a,b, Chun Gwon Park a,b,g,h,*
a Department of Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Suwon, Gyeonggi 16419, Republic of Korea b Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, Republic of Korea c Institute of Medical and Biological Engineering, Medical Research Center, Seoul National University, Seoul 03080, Republic of Korea. d Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University (SKKU), Suwon, Gyeonggi 16419, Republic of Korea e Department of Bioengineering, Hanyang University, Seoul 04763, Republic of Korea f School of Integrative Engineering, Chung-Ang University, 84, Heukseok-ro, Dongjak-gu, Seoul 06974, Republic of Korea g Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Suwon, Gyeonggi 16419, Republic of Korea h Center for Neuroscience Imaging Research, Institute for Basic Science (IBS), Suwon, Gyeonggi 16419, Republic of Korea
* Corresponding author
1 These authors contributed equally to this work.
Abstract
Inflammatory bowel diseases (IBDs) are idiopathic gastrointestinal inflammatory disorders featuring chronic intestinal inflammation. Although IBDs are increasingly becoming globally prevalent, the exact etiology of IBD remains obscure. Recently, the ability of various drugs for mucosal healing such as corticosteroids, antibiotics, and immunosuppressants has been proven. However, the delivery of free drugs is insufficient and inadequate since some patients have experienced reduced efficacy due to repeated administration and others have suffered side effects. In this regard, novel platforms based on biomaterials are required to deliver pharmaceutical agents to the damaged site with increased efficacy and reduced side effects. In this review, we summarize the most recent status of numerous biomaterials in treating IBD. This review addresses various nanoparticles, microparticles, and hydrogels recently prepared from natural polymers, lipids, synthetic polymers, and inorganic materials. These diverse biomaterials can be used as effective drug-delivery systems to promote colon-specific delivery and for the stable release of drugs in IBD treatments.
논문정보
- Review Paper
- 2022년 05월 (BRIC 등록일 2022-05-25)
- 국내 연구진
- 바이오·의료융합 > 바이오소재
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
